Skip to main content

Home/ Cancer/ Group items tagged prostate

Rss Feed Group items tagged

Matti Narkia

The cancer 'TRAP' - 2 views

  •  
    "Worcester, MA - Current research suggests that TNF-receptor associated protein-1 (TRAP-1) may prevent cancer cell death. The related report by Leav et al, "Cytoprotective Mitochondrial Chaperone TRAP-1 as a Novel Molecular Target in Localized and Metastatic Prostate Cancer," appears in the January 2010 issue of the American Journal of Pathology.

    Prostate cancer cells are often resistant to cell death. Researchers led by Dr. Dario C. Altieri of the University of Massachusetts Medical School, therefore, explored the role of TRAP-1, a protein thought to regulate cell death, in prostate cancer survival. TRAP-1 was highly expressed in both high-grade human prostate cancer lesions and mouse models of prostate cancer, but not in benign or normal prostate tissue. In addition, TRAP-1 overexpression in non-cancer prostate cells inhibited cell death, whereas TRAP-1-deficient prostate cancer cells had enhanced levels of cell death. Moreover, treatment with Gamitrinib, which inhibits TRAP-1, resulted in prostate cancer cell death, but not death of non-cancerous prostate cells. Therefore, targeting TRAP-1 via Gamitrinib treatment may be a viable therapeutic strategy for patients with advanced prostate cancer."
Matti Narkia

Briefing: Cannabis compounds fight prostate cancer - health - 19 August 2009 - New Scie... - 2 views

  •  
    "Compounds similar to those found in cannabis have been shown to stop prostate cancer cells from multiplying. Two cannabinoid compounds, JWH-015 and MET, stopped prostate tumour growth in human prostate cells in Petri dishes and also in mice with the disease. They halted the cell-division cycle and killed the cancer cells, and had the greatest effect on aggressive prostate cancer cell types, which do not respond to hormone treatments.

    Some 192,000 men in the US alone are diagnosed with prostate cancer each year, and researchers Inés Díaz-Laviada Marturet at the University of Alcalá, Spain, and her colleagues say the results could offer hope to those affected. But before you go looking for a dealer, New Scientist answers a few questions"
Matti Narkia

Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependen... - 0 views

  •  
    Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells.
    Mantena SK, Sharma SD, Katiyar SK.
    Mol Cancer Ther. 2006 Feb;5(2):296-308.
    PMID: 16505103
    doi: 10.1158/1535-7163.MCT-05-0448

    The effectiveness of berberine in checking the growth of androgen-insensitive, as well as androgen-sensitive, prostate cancer cells without affecting the growth of normal prostate epithelial cells indicates that it may be a promising candidate for prostate cancer therapy.

    The evaluation of ancient herbal medicines may indicate novel strategies for the treatment of prostate cancer, which remains the leading cause of cancer-related deaths in American men (1). In our present investigation, we show that a naturally occurring isoquinoline alkaloid, berberine, significantly inhibits the proliferation and reduces the viability of DU145 and PC-3 as well as LNCaP cells (Fig. 1), which suggests that berberine may be an effective chemotherapeutic agent against both androgen-sensitive and androgen-insensitive prostate cancer cells. Importantly, we found that berberine did not exhibit toxicity to nonneoplastic human prostate epithelial cells under the conditions used, except for a moderate reduction in cell viability at higher concentrations when cells were treated in vitro for an extended period of time.

    In conclusion, the results of the present study indicate that berberine inhibits proliferation and induces G1-phase arrest and apoptosis in human prostate cancer cells but not in normal human prostate epithelial cells. In addition, we provide mechanistic evidence that berberine-induced apoptosis in prostate carcinoma cells, particularly hormone-refractory prostate carcinoma cells, is mediated through enhanced expression of Bax, disruption of the mitochondrial membrane potential, and activation of caspase-3.
Matti Narkia

Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids - Journal... - 0 views

  •  
    Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids.
    Berquin IM, Min Y, Wu R, Wu J, Perry D, Cline JM, Thomas MJ, Thornburg T, Kulik G, Smith A, Edwards IJ, D'Agostino R, Zhang H, Wu H, Kang JX, Chen YQ.
    J Clin Invest. 2007 Jul;117(7):1866-75.
    PMID: 17607361

    Our data suggest that modulation of prostate cancer development by polyunsaturated fatty acids is mediated in part through Bad-dependent apoptosis. This study highlights the importance of gene-diet interactions in prostate cancer.
Matti Narkia

How to Optimize Vitamin D Supplementation to Prevent Cancer, Based on Cellular Adaptati... - 0 views

  •  
    How to optimize vitamin D supplementation to prevent cancer, based on cellular adaptation and hydroxylase enzymology.
    Vieth R.
    Anticancer Res. 2009 Sep;29(9):3675-84. Review.
    PMID: 19667164
Matti Narkia

The Relevance of Vitamin D Receptor (VDR) Gene Polymorphisms for Cancer: A Review of th... - 0 views

  •  
    The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature.
    Köstner K, Denzer N, Müller CS, Klein R, Tilgen W, Reichrath J.
    Anticancer Res. 2009 Sep;29(9):3511-36. Review.
    PMID: 19667145

    CONCLUSION: Significant associations with VDR polymorphisms have been reported in cancer of the breast (Fok1, Bsm1, Taq1, Apa1, poly (A)), prostate (Fok1, Bsm1, Taq1, poly (A)), skin (Fok1, Bsm1, A-1210), colorectum (Fok1, Bsm1), ovary (Fok1, Apa1) and bladder (Fok1), and in renal cell carcinoma (Taq1, Apa1). However, conflicting data have been reported for most malignancies. After careful evaluation of the actual literature, it can be summarized that data indicating an association of VDR polymorphisms and cancer risk are strongest for breast cancer (Bsm1, Fok1), prostate cancer (Fok1) and malignant melanoma (MM) (Fok1). Data indicating an association of VDR polymorphisms and cancer prognosis are strongest for prostate cancer (Fok1), breast cancer (Bsm1, Taq1), MM (Bsm1) and renal cell carcinoma (Taq1).
Matti Narkia

A multicountry ecologic study of risk and risk reduction factors for prostate cancer mo... - 0 views

  •  
    A multicountry ecologic study of risk and risk reduction factors for prostate cancer mortality.
    Grant WB.
    Eur Urol. 2004 Mar;45(3):271-9.
    PMID: 15036670

    CONCLUSIONS: These results are consistent with insulin-like growth factor-I (IGF-I), being an important risk factor for prostate cancer, with alcohol and calcium being less important risk factors, and with allium family vegetables, and, to a lesser extent, vitamin D being important risk reduction factors. These results should provide guidance for additional studies on dietary and environmental links to prostate cancer.
Matti Narkia

The Role of Vitamin D in Cancer Prevention -- Garland et al. 96 (2): 252 -- American Jo... - 0 views

  •  
    The role of vitamin D in cancer prevention.
    Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, Holick MF.
    Am J Public Health. 2006 Feb;96(2):252-61. Epub 2005 Dec 27. Review.
    PMID: 16380576
    DOI: 10.2105/AJPH.2004.045260

    Vitamin D status differs by latitude and race, with residents of the northeastern United States and individuals with more skin pigmentation being at increased risk of deficiency. A PubMed database search yielded 63 observational studies of vitamin D status in relation to cancer risk, including 30 of colon, 13 of breast, 26 of prostate, and 7 of ovarian cancer, and several that assessed the association of vitamin D receptor genotype with cancer risk.

    The majority of studies found a protective relationship between sufficient vitamin D status and lower risk of cancer. The evidence suggests that efforts to improve vitamin D status, for example by vitamin D supplementation, could reduce cancer incidence and mortality at low cost, with few or no adverse effects
Matti Narkia

Vitamin D and the epidemiology of prostate cancer. - Semin Dial. 2005 Jul-Aug;18(4):276... - 0 views

  •  
    Vitamin D and the epidemiology of prostate cancer.
    Schwartz GG.
    Semin Dial. 2005 Jul-Aug;18(4):276-89. Review.
    PMID: 16076349
    DOI: 10.1111/j.1525-139X.2005.18403.x
Matti Narkia

Association between serum 25(OH)D and death from prostate cancer - British Journal of C... - 0 views

  •  
    Association between serum 25(OH)D and death from prostate cancer.
    Tretli S, Hernes E, Berg JP, Hestvik UE, Robsahm TE.
    Br J Cancer. 2009 Feb 10;100(3):450-4. Epub 2009 Jan 20.
    PMID: 19156140
    doi:10.1038/sj.bjc.6604865

    The serum level of 25(OH)D may be involved in disease progression and is a potential marker of prognosis in patients with prostate cancer.
Matti Narkia

Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse... - 0 views

  •  
    Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy.
    Woo TC, Choo R, Jamieson M, Chander S, Vieth R.
    Nutr Cancer. 2005;51(1):32-6.
    PMID: 15749627
Matti Narkia

Mayo researchers: Dramatic outcomes in prostate cancer study - 0 views

  •  
    ROCHESTER, Minn. -- Two Mayo Clinic patients whose prostate cancer had been considered inoperable are now cancer free thanks in part to an experimental drug therapy that was used in combination with standardized hormone treatment and radiation therapy. The men were participating in a clinical trial of an immunotherapeutic agent called MDX-010 or ipilimumab. In these two cases, physicians say the approach initiated the death of a majority of cancer cells and caused the tumors to shrink dramatically, allowing surgery. In both cases, the aggressive tumors had grown well beyond the prostate into the
Matti Narkia

Green tea 'slows prostate cancer' - BBC NEWS | Health - 0 views

  •  
    A chemical found in green tea appears to slow the progression of prostate cancer, a study has suggested.
    Green tea has been linked to a positive effect on a wide range of conditions, including heart disease, cancer and Alzheimer's disease.
Matti Narkia

Carbohydrate restriction may slow prostate tumor growth - eurekalert.org - 0 views

  •  
    DURHAM, N.C. -- Restricting carbohydrates, regardless of weight loss, appears to slow the growth of prostate tumors, according to an animal study being published this week by researchers in the Duke Prostate Center.

    "Previous work here and elsewhere has shown that a diet light in carbohydrates could slow tumor growth, but the animals in those studies also lost weight, and because we know that weight loss can restrict the amount of energy feeding tumors, we weren't able to tell just how big an impact the pure carbohydrate restriction was having, until now," said Stephen Freedland, M.D., a urologist in the Duke Prostate Center and lead investigator on this study.

    The researchers believe that insulin and insulin-like growth factor contribute to the growth and proliferation of prostate cancer, and that a diet devoid of carbohydrates lowers serum insulin levels in the bodies of the mice, thereby slowing tumor growth, Freedland said.
Matti Narkia

Novel therapy for cancer? from medicineworld.org - 0 views

  •  
    A ground-breaking Canada-wide clinical trial led by Dr. Katherine Borden, at the Institute for Research in Immunology and Cancer (IRIC) of the Universit de Montral, has shown that a common anti-viral drug, ribavirin, can be beneficial in the treatment of cancer patients. Published in the journal Blood (First Edition), the study demonstrates that ribavirin suppresses the activities of the eIF4E gene in patients. This gene is dysregulated in 30 percent of cancers including breast, prostate, head and neck, colon and stomach cancer.
Matti Narkia

White button mushroom (Agaricus bisporus) exhibits antiproliferative and proapoptotic p... - 0 views

  •  
    White button mushroom (Agaricus bisporus) exhibits antiproliferative and proapoptotic properties and inhibits prostate tumor growth in athymic mice.
    Adams LS, Phung S, Wu X, Ki L, Chen S.
    Nutr Cancer. 2008;60(6):744-56.
    PMID: 19005974
Matti Narkia

Serum Vitamin D and Risk of Prostate Cancer in a Case-Control Analysis Nested Within th... - 0 views

  •  
    Serum Vitamin D and Risk of Prostate Cancer in a Case-Control Analysis Nested Within the European Prospective Investigation into Cancer and Nutrition (EPIC).
    Travis RC, Crowe FL, Allen NE, Appleby PN, Roddam AW, Tjønneland A, Olsen A, Linseisen J, Kaaks R, Boeing H, Kröger J, Trichopoulou A, Dilis V, Trichopoulos D, Vineis P, Palli D, Tumino R, Sieri S, Bueno-de-Mesquita HB, van Duijnhoven FJ, Chirlaque MD, Barricarte A, Larrañaga N, González CA, Argüelles MV, Sánchez MJ, Stattin P, Hallmans G, Khaw KT, Bingham S, Rinaldi S, Slimani N, Jenab M, Riboli E, Key TJ.
    Am J Epidemiol. 2009 Apr 9. [Epub ahead of print]
    PMID: 19359375
    doi:10.1093/aje/kwp022
Matti Narkia

White Button Mushroom (Agaricus Bisporus) Exhibits Antiproliferative and Proapoptotic P... - 0 views

  •  
    White button mushroom (Agaricus bisporus) exhibits antiproliferative and proapoptotic properties and inhibits prostate tumor growth in athymic mice.
    Adams LS, Phung S, Wu X, Ki L, Chen S.
    Nutr Cancer. 2008;60(6):744-56.
    PMID: 19005974
    DOI: 10.1080/01635580802192866
Matti Narkia

Vitamin D and Intervention Trials in Prostate Cancer: From Theory to Therapy - 0 views

  •  
    Vitamin D and intervention trials in prostate cancer: from theory to therapy.
    Schwartz GG.
    Ann Epidemiol. 2009 Feb;19(2):96-102. Epub 2008 Jul 10.
    PMID: 18619854
    doi:10.1016/j.annepidem.2008.03.007

    This suggests that whereas vitamin D (e.g., cholecalciferol) might prevent prostate cancer, existing prostate tumors likely would require treatment with 1,25(OH)(2)D and/or its analogs. The major obstacle to the use of 1,25(OH)(2)D in patients therapeutically is the risk of hypercalcemia. Several maneuvers to reduce this risk, including pulse dosing and the use of less calcemic 1,25(OH)(2)D analogs, have been explored in Phase I-III clinical trials. Once merely a promise, vitamin D-based therapies for prostate cancer may soon be medical practice.
Matti Narkia

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependen... - 0 views

  •  
    CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.
    Ang JE, Olmos D, de Bono JS.
    Br J Cancer. 2009 Mar 10;100(5):671-5. Epub 2009 Feb 17.
    PMID: 19223900
    doi:10.1038/sj.bjc.6604904
1 - 20 of 80 Next › Last »
Showing 20 items per page